stockrowGSK PLC Sponsored ADR
GSK Healthcare Drug Manufacturers General
GSK PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $43.1 billion, up 7.44% from fiscal 2024.
- Revenue
- +3.75%
- EPS
- −14.7%
- Free cash flow
- +62.4%
- Total debt
- +33.2%
Quarter to September 2026, against a year earlier
Follow GSK
Alert me
GSK PLC Sponsored ADR (GSK) Operating cash flow
GSK PLC Sponsored ADR's operating cash flow for fiscal 2025 was $10.2B, up 21.9% from $8.4B in fiscal 2024. Over the twelve months to 30 September 2026 it was $11.8B. Over the past ten years it has ranged from $3.9B (fiscal 2015) to $11.2B (fiscal 2018); the current reading is higher than 64% of that period. GSK PLC Sponsored ADR ranks 12th of 21 Drug Manufacturers General companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | $10.2B | 21.88% |
| FY2024 | $8.4B | (0.52%) |
| FY2023 | $8.4B | (8.06%) |
| FY2022 | $9.2B | (16.26%) |
| FY2021 | $10.9B | 0.89% |
| FY2020 | $10.8B | 5.83% |
| FY2019 | $10.2B | (8.89%) |
| FY2018 | $11.2B | 26.07% |
| FY2017 | $8.9B | 1.26% |
| FY2016 | $8.8B | 124.17% |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Sep 2026 | $3.8B | 5.12% |
| Jun 2026 | $3.6B | 134.41% |
| Mar 2026 | $1.5B | (45.95%) |
| Dec 2025 | $2.8B | (6.27%) |
| 43 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| SNY Sanofi compare | $23.8B |
| NVO Novo Nordisk A/S compare | $20.4B |
| GILD Gilead Sciences, Inc. compare | $14.5B |
| PFE Pfizer Inc. compare | $14.2B |
| AZN AstraZeneca PLC compare | $13.2B |
| AMGN Amgen Inc. compare | $12.0B |
| GSK GSK PLC Sponsored ADR | $11.8B |
| BMY Bristol Myers Squibb Company compare | $10.7B |
| BIIB Biogen Inc. compare | $2.2B |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on GSK
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement